Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
MEDP
Strong BuyMedpace Holdings, Inc. · Healthcare · United States · $16.8B · Avg Vol: $182M/d
COMPANY DESCRIPTION
Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) providing clinical development services to biopharmaceutical and medical device companies. The company specializes in scientifically-driven clinical trials, particularly for small to mid-sized biopharma firms, offering a comprehensive and integrated approach. Its deep therapeutic expertise, operational efficiency, and focus on complex, high-quality trials provide a strong competitive moat within the specialized CRO market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.5B | 1.9B | 2.1B | 2.5B | 20.1% | 2.8B | 2.9B | 3.0B | 9.4% |
| EPS | 5.06 | 7.57 | 9.20 | 13.06 | 15.64 | 32.6% | 17.05 | 18.12 | 19.77 | 12.4% |
| Shares | — | 31.1M | 30.8M | 30.6M | 28.4M | -8.8% | 27.9M | — | — | — |
| Debt | — | 188.9M | 142.1M | 126.2M | 113.6M | -15.6% | 144.1M | — | — | — |
| Equity | — | 386.4M | 559.0M | 825.5M | 459.1M | 5.9% | — | — | — | — |
| Op CF | — | 388.1M | 433.4M | 608.8M | 713.2M | 22.5% | 752.7M | — | — | — |
| Inv CF | — | -38.7M | -34.6M | -28.3M | -31.1M | — | — | — | — | — |
| Fin CF | — | -775.8M | -182.6M | -154.0M | -860.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MEDP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc.(you) | $16.8B | 84 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $26.8B | 85 | Strong Buy |
| LH | Labcorp Holdings Inc. | $27.2B | 86 | Strong Buy |
| ILU.DE | Illumina, Inc. | $33.3B | 88 | Strong Buy |
| RVTY | Revvity, Inc. | $14.4B | 67 | Buy |
| A1GI34.SA | Agilent Technologies, Inc. | $39.1B | 87 | Strong Buy |
| CRL | Charles River Laboratories International, Inc. | $14.0B | 65 | Hold |
| IQV | IQVIA Holdings Inc. | $43.1B | 78 | Buy |
| SHC | Sotera Health Company | $5.5B | 80 | Buy |
| IDXX.MX | IDEXX Laboratories, Inc. | $43.9B | 73 | Buy |
Peer medians: ROE -25.0% · P/E 30.3x · Gross margin 58.8%